| Customization: | Available |
|---|---|
| Dosage Form: | Injection |
| Transport Package: | Carton |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Tranexamic Acid Injection 1g/10ml |
| Strength | 1g/10ml |
| Packing | 5ampoules/box |
| Origin | China |
This product is mainly used for the treatment of acute or chronic, localized or systemic primary fibrinolysis especially caused by various bleeding, this product can also be used for:
1. Trauma or surgical bleeding of organs rich in plasminogen activators such as prostate, urethra, lung, brain, uterus, adrenal gland and thyroid gland;
2. Used as an antagonist of tissue plasminogen activator (t-PA) streptokinase and urokinase;
3. Induced abortion, early peeling of placenta, stillbirth, fibrinolytic bleeding due to amniotic fluid embolism, and pathologic intrauterine hypermenorrhagia with local fibrinolytic increase;
4. Used to prevent or alleviate bleeding after tooth extraction or oral surgery in hemophiliacs with factor VIII or factor IX deficiency;
5. Mild hemorrhage caused by central neuropathy, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage, is better than other antifibrinolytic drugs in hemostasis, but attention must be paid to the risk of complicated cerebral edema or cerebral infarction; For patients with severe surgical indications, this product can only be used as adjunct medication;
6. For the treatment of hereditary angioneurotic edema, which can reduce the frequency and severity of its attacks;
7. Hemophilia patients with active bleeding can be combined with this drug.
1. Patients using this product should be monitored for the possibility of thrombosis complications. It should be used with caution for those prone to thrombosis.
2. For secondary hyperfibrinolysis caused by diffuse intravascular coagulation, this product should be used with caution before heparinization.
3. Use with caution when hemophilia or pyeloparenchymal disease occurs in large amounts of hematuria.
4. Heparin is safer to treat hypofibrinogenemia bleeding caused by intrauterine stillbirth.
5. Dosage should be reduced in patients with chronic renal insufficiency due to the high concentration of drugs in urine after administration.
6. The dosage of this product should also be reduced when treating bleeding during prostate surgery.
7. Those who must use this product continuously should be monitored by eye examination (such as vision test, vision, visual field and fundus).
This product can transplacenta and can be secreted in milk, so pregnant and lactating women should be cautious.
){kind=link}